Navigation Links
Sundia MediTech and Xcovery Announce Big Success in Drug Discovery
Date:2/10/2009

SHANGHAI, China, Feb. 10 /PRNewswire-Asia/ -- Sundia MediTech, a CRO company based in Shanghai, China and Xcovery, a company based in Florida, U.S.A. jointly announced their 2 year collaborative success in new drug discovery at IBC's BioProcess International Conference yesterday in San Diego, USA. So far their collaboration has achieved 4 pre-clinic candidates, with 2 more candidates to be identified within the next 3 months. Dr. Xiaochuan Wang, CEO of Sundia MediTech Company and Ms. Teri A. Swift, Vice President for Business Development of Xcovery, made the announcement together.

Both of Xcovery's founders are legendary figures in the U.S. biotech industry. Mr. Sherry Snyder, CEO of the company, is a pioneer and leader of this industry with significant contributions towards its development. In his professional career, he founded different companies including the well-known biotech company Genzyme. Company CSO Dr. Chris Liang earned his reputation as a leading drug discovery expert from his leadership and contribution to the discovery of Sutent, Pfizer's leading anti-cancer drug. In recent years, he continued to achieve multiple successes in drug discovery.

In 2006, Mr. Snyder invited Dr. Liang to start a new drug discovery company Xcovery. They abandoned the old model of using internal resources to do research and utilized almost 100% CRO resources for R&D work instead. After evaluating many CRO companies, amongst more than 10 in China they selected Sundia as their CRO service provider. "We are honored to have the opportunity of providing R&D service to Xcovery," said Sundia's CEO Dr. Xiaochuan Wang. "It is Sundia's objective to provide high end CRO service with rich R&D content to our clients. We have successfully identified 12 new pre-clinic candidates for our client companies from different countries."

According to Dr. Chris Liang, the result of Xcovery's collaboration with Sundia was much better than they expected. They got 4 (possibly 6) pre-clinic products in merely 2.5 years. Compared to their initial target, the research efficiency and outcome is ten folds higher. Mr. Snyder commented: "The value of this collaboration is not only in the pre-clinic candidates we've generated, but more importantly it sets a precedent as the most efficient and economical model for new drug discovery."

About the Companies:

Xcovery is a new biotechnology company spun out from The Scripps Research Institute by Sherry Snyder (CEO) and Chris Liang (CSO), with the support of several prominent academic partners. Xcovery develops next generation kinase therapeutics for cancer and inflammatory diseases more rapidly and economically than current approaches.

Sundia MediTech Company was founded in Shanghai in 2004 by a group of veterans of the US pharmaceutical industry to provide drug discovery and pharmaceutical development CRO services to clients worldwide. Over the past 5 years, Sundia has built a strong reputation as a leading CRO Company in China.


'/>"/>
SOURCE Sundia MediTech Company
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Sundia MediTech Ranked #16 in Deloitte Technology Fast 50 China
2. AMICAS Announces Integrations at More Than 100 MEDITECH Facilities
3. Weed Science Society of America Announces Winners in Annual Scientific Awards Program
4. Beckman Coulter Announces Fourth Quarter and Full Year 2008 Results; Earnings Outlook Achieved on Strong Fundamentals
5. Sagent Pharmaceuticals Announces Expansion of Cefazolin Product Line to Include Cefazolin for Injection, USP in 500mg Single-Dose Vial
6. LAB Research announces changes to its Board of Directors
7. SENOMYX ANNOUNCES INITIATION OF DEVELOPMENT ACTIVITIES FOR NEW BITTER BLOCKERS
8. PacificGMP and LigoCyte Pharmaceuticals Announce cGMP Manufacturing Collaboration
9. Diffusion Pharmaceuticals Announces Completion of a $2.9 Million Private Placement and Company Presentations at Upcoming Industry Conferences in Geneva, Switzerland and Naples, Florida
10. Stereotaxis Announces Fourth Quarter and Full Year 2008 Earnings Release Date and Conference Call
11. Amicus Therapeutics Announces Fourth Quarter and Full Year 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and ... and the 6000i models are higher end machines that use the more unconventional z-dimension ... light beam from the bottom of the cuvette holder. , FireflySci has developed ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge (BDC), ... new ways to harness living systems and biotechnology, announced ... (MoMA) in New York City . ... participating students, showcased projects at MoMA,s Celeste Bartos Theater ... Antonelli , MoMA,s senior curator of architecture and design, ...
(Date:6/23/2016)... LOUISVILLE, Ky. , June 23, 2016 /PRNewswire/ ... from two Phase 1 clinical trials of its ... double-blind, placebo-controlled, single and multiple ascending dose studies ... and pharmacodynamics (PD) of subcutaneous injection in healthy ... APL-2 subcutaneously (SC) either as a single dose ...
Breaking Biology Technology:
(Date:5/12/2016)... May 12, 2016 WearablesResearch.com , a ... the overview results from the Q1 wave of its ... wave was consumers, receptivity to a program where they ... a health insurance company. "We were surprised ... says Michael LaColla , CEO of Troubadour Research, ...
(Date:4/28/2016)... April 28, 2016 First quarter 2016:   ... 966% compared with the first quarter of 2015 The ... 589.1 M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) ... guidance is unchanged, SEK 7,000-8,500 M. The operating margin ...
(Date:4/15/2016)...  A new partnership announced today will help ... in a fraction of the time it takes ... life insurance policies to consumers without requiring inconvenient ... Diagnostics, rapid testing (A1C, Cotinine and HIV) and ... weight, pulse, BMI, and activity data) available at ...
Breaking Biology News(10 mins):